# SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

> **NCT04952402** · PHASE4 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 43 (actual)

## Conditions studied

- Covid19
- SARS-CoV2 Infection

## Interventions

- **BIOLOGICAL:** Study-provided Moderna mRNA-1273 COVID-19 vaccine
- **BIOLOGICAL:** Community-provided Moderna mRNA-1273 COVID-19 Vaccine
- **BIOLOGICAL:** Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT04952402
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-09
- **Primary completion:** 2022-02-28
- **Final completion:** 2023-01-10
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952402, "SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04952402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*